Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

PHASE2CompletedINTERVENTIONAL
Enrollment

501

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

June 7, 2017

Study Completion Date

June 7, 2017

Conditions
Atherosclerotic Cardiovascular DiseaseFamilial HypercholesterolemiaDiabetes
Interventions
DRUG

ALN-PCSSC

ALN-PCSSC is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis and is given as SC injections

DRUG

Normal Saline

Saline (sterile, normal, 0.9%) solution given as SC injections

Trial Locations (54)

10029

Mount Sinai Icahn School of Medicine, New York

12203

Medical University Berlin, Berlin

20251

University Heart Center Hamburg, Hamburg

23294

National Clinical Research, Inc., Richmond

32216

Jacksonville Center for Clinical Research, Jacksonville

37745

Wellmont CVA Heart Institute, Greeneville

45227

Metabolic And Atherosclerosis Research Center, Cincinnati

45246

Sterling Research Group, Cincinnati

45355

Medical Center Essen, Essen

46260

Midwest Institute For Clinical Research, Indianapolis

60590

University Hospital Frankfurt, Frankfurt

69120

Medical University Hospital Heidelberg, Internal medicine III, Heidelberg

79106

Amarillo Heart Clinical Research Institute, Inc., Amarillo

80636

Technical University Munich, German Heart Center, Munich

V6Z 1Y6

St. Paul's Hospital, Vancouver

R2H 2A6

St. Boniface Hospital, Winnipeg

A1B 3V6

Eastern Regional Health Authority, Patient Research Centre, St. John's

L6Z 4N5

Brampton Research Associates, Brampton

N6C 2R5

Lawson Health Research Institute, London

M5C 2T2

St. Michael's Hospital, Toronto

G7H 7K9

ECOGENE-21 Clinical Trials Center, Chicoutimi

H1T 3Y7

Clinic Sante Cardio MC, Montreal

H2W 1R7

Institut de Recherches Cliniques de Montreal, Montreal

G1V 4G5

Université Laval Quebec, Québec

G1V 4W2

Clinique des maladies lipidique Quebec, Québec

J1H 5N4

Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke

1105 AZ

Amsterdam Medical Center, Amsterdam

7416 SE

Deventer Ziekenhuis, Deventer

5611 NV

Andromed Eindhoven, Eindhoven

4462 RA

Admiraal de Ruyter Hospital, Cardiology, Goes

7909 AA

Bethesda Diabetes Research Center, Hoogeveen

9603 AE

Medisch Centrum Gorecht, Hoogezand

0031229284320

VOC Hoorn, Hoorn

2333 ZA

Leids Universitair Medisch Centrum (LUMC), Leiden

3021 HC

Andromed Rotterdam, Rotterdam

2545 CH

Haga Hospital, The Hague

3582 KE

Diakonessenhuis, Vascular Policlinic, Utrecht

3584 CX

UMC Utrecht, Utrecht

5912 BL

VieCurie Venlo, Cardiology, Venlo

3331 LZ

Albert Schweitzer Hospital, Cardiology, Zwijndrecht

B15 2TH

Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham

EH16 4SA

Edinburgh Royal Infirmary, Edinburgh

EX2 5DW

The Royal Devon and Exeter NHS Trust, Exeter

PL23 1DT

Fowey River Practice, Fowey

HP11 2TT

Buckinghamshire NHS Trust, High Wycombe

Oak Tree Surgery

Oak Tree Surgery, Liskeard

NW3 2QG

Royal Free Hospital, London

M13 9WL

Central Manchester University Hospital NHS Foundation Trust, Manchester

NE1 4LP

The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne

TR18 4JH

The Alverton Practice, Penzance

PL5 3JB

Knowle House Surgery, Plymouth

St. Austell

Brannel Surgery, St Austell

PL11 2TB

Rame Medical Ltd (Rame Research), Torpoint

WR5 1DD

Worcestershire Acute NHS Trust, Worcester

Sponsors
All Listed Sponsors
lead

The Medicines Company

INDUSTRY

NCT02597127 - Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C) | Biotech Hunter | Biotech Hunter